Karen Chagin

Dr. Karen Chagin is highly experienced in clinical development including extensive experience in cellular therapy. She spent nearly a decade building cellular therapy programs from proof of concept to the late-stage clinical setting. Previously, Dr. Chagin was Vice President of Clinical Development at Adaptimmune LLC, where she was responsible for the strategy and execution of global clinical development programs studying novel engineered T-cell receptor therapies in solid tumors on a global platform. Prior to that, she served as a Scientific Director in Oncology Early Development at Janssen leading development activities for Phase 1 assets. Dr. Chagin began her career in the pharmaceutical industry at GlaxoSmithKline. As Medical Director in clinical development at GSK, she was responsible for the development and execution of multiple Phase 2 and 3 clinical studies in a variety of solid and hematologic malignancies. Dr. Chagin also led and contributed to the registration of several oncology products and indications globally.

Dr. Chagin trained as a pediatric Hematologist/Oncologist at The Children’s Hospital of Philadelphia and holds and M.D from Temple University School of Medicine.